FUSN — Fusion Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.80bn
- $1.61bn
- $2.07m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 1.44 | 1.46 | 2.07 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 18.2 | 37.9 | 83.5 | 89.5 | 101 |
Operating Profit | -18.2 | -37.9 | -82 | -88 | -99.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -15.9 | -75.7 | -81.2 | -89.4 | -94.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.2 | -78.3 | -81 | -87.6 | -94.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.2 | -78.3 | -81 | -87.6 | -94.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.2 | -79.7 | -81 | -87.6 | -94.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.389 | -1.91 | -1.9 | -2 | -1.45 |
Dividends per Share |